Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time. This event presents an opportunity for investors and industry professionals to gain insights into Seer's innovative platform and business strategies.
Interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website after the conference concludes. This participation underscores Seer's commitment to engaging with the investment community and showcasing its advancements in the proteomics field.
Seer, un'azienda pionieristica nel campo delle scienze della vita focalizzata sulla proteomica, ha annunciato la sua partecipazione alla 22° Conferenza Annuale Globale sulla Salute di Morgan Stanley a New York. Il team di gestione dell'azienda parteciperà a un fireside chat giovedì 5 settembre alle 16:05 ora orientale. Questo evento rappresenta un'opportunità per investitori e professionisti del settore di ottenere approfondimenti sulla piattaforma innovativa di Seer e sulle strategie aziendali.
Le parti interessate possono accedere a un webcast dal vivo della sessione attraverso la sezione Investitori del sito web di Seer all'indirizzo investor.seer.bio. Per coloro che non possono partecipare in tempo reale, sarà disponibile una replay archiviata sul sito web dell'azienda dopo il termine della conferenza. Questa partecipazione sottolinea l'impegno di Seer nel coinvolgere la comunità di investitori e nel mostrare i suoi progressi nel campo della proteomica.
Seer, una empresa pionera en el campo de las ciencias de la vida centrada en la proteómica, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley en Nueva York. El equipo directivo de la empresa participará en un fireside chat el jueves 5 de septiembre a las 4:05 p.m. hora del Este. Este evento presenta una oportunidad para que inversores y profesionales de la industria obtengan información sobre la plataforma innovadora de Seer y sus estrategias empresariales.
Las partes interesadas pueden acceder a una transmisión en vivo de la sesión a través de la sección de Inversores del sitio web de Seer en investor.seer.bio. Para aquellos que no puedan asistir en tiempo real, se hará disponible una repetición archivada en el sitio web de la empresa después de que concluya la conferencia. Esta participación subraya el compromiso de Seer de interactuar con la comunidad de inversores y de mostrar sus avances en el campo de la proteómica.
Seer는 단백질체학에 초점을 맞춘 선도적인 생명과학 회사로서 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 9월 5일 목요일 동부 표준시 오후 4시 5분에 파이어사이드 챗에 참여할 예정입니다. 이 행사는 투자자와 업계 전문가들이 Seer의 혁신적인 플랫폼 및 비즈니스 전략에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
관심 있는 분들은 Seer 웹사이트의 투자자 섹션에서 실시간 웹캐스트에 접근할 수 있습니다: investor.seer.bio. 실시간으로 참석할 수 없는 분들을 위해 컨퍼런스 종료 후 회사 웹사이트에 아카이브 재생이 제공될 예정입니다. 이 참여는 Seer가 투자 커뮤니티와 소통하고 단백질체학 분야에서의 발전을 선보이려는 의지를 강조합니다.
Seer, une entreprise pionnière dans le domaine des sciences de la vie axée sur la protéomique, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley à New York. L'équipe de direction de l'entreprise participera à une discussion informelle le jeudi 5 septembre à 16h05, heure de l'Est. Cet événement représente une occasion pour les investisseurs et les professionnels de l'industrie d'obtenir des perspectives sur la plateforme novatrice de Seer et ses stratégies commerciales.
Les parties intéressées peuvent accéder à un webinaire en direct de la session via la section Investisseurs du site Web de Seer à l'adresse investor.seer.bio. Pour ceux qui ne peuvent pas participer en temps réel, un replay archivé sera rendu disponible sur le site Web de l'entreprise après la conférence. Cette participation souligne l'engagement de Seer envers la communauté des investisseurs et met en avant ses avancées dans le domaine de la protéomique.
Seer, ein Pionierunternehmen im Bereich der Lebenswissenschaften, das sich auf Proteomik konzentriert, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley in New York bekannt gegeben. Das Managementteam des Unternehmens wird am Donnerstag, den 5. September um 16:05 Uhr Eastern Time an einem Fireside Chat teilnehmen. Diese Veranstaltung bietet Investoren und Fachleuten der Branche die Möglichkeit, Einblicke in die innovative Plattform und die Geschäftsstrategien von Seer zu erhalten.
Interessierte Parteien können den Live-Stream der Sitzung über den Investorenbereich der Seer-Website unter investor.seer.bio abrufen. Für diejenigen, die nicht in Echtzeit teilnehmen können, wird nach Abschluss der Konferenz ein archivierter Replay auf der Unternehmenswebsite zur Verfügung gestellt. Diese Teilnahme unterstreicht Seers Engagement, mit der Investmentgemeinschaft in Kontakt zu treten und die Fortschritte im Bereich der Proteomik zu präsentieren.
- None.
- None.
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
Seer’s management is scheduled to participate in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time / 1:05 p.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact:
Carrie Mendivil
investor@seer.bio
Media Inquiries:
Patrick Schmidt
pr@seer.bio
FAQ
When is Seer (SEER) participating in the Morgan Stanley Healthcare Conference?
How can I watch Seer's (SEER) presentation at the Morgan Stanley conference?
What type of company is Seer (SEER)?
Where is the Morgan Stanley Healthcare Conference that Seer (SEER) is attending taking place?
